Oxford Optronix has announced the formal launch of its next-generation OxyLite™ Pro and OxyFlo™ Pro systems for tissue oxygenation and blood flow monitoring - delivering the most advanced tissue vitality monitoring platform on the market.
This latest release marks the third generation of the company’s OxyLite™ and OxyFlo™ brand systems, first launched in 1991.
The OxyLite and OxyFlo systems are unique modular instruments that utilize fibre-optic micro-sensors to provide real-time measurements of local tissue oxygenation (ptiO2), tissue blood perfusion (blood flow) and tissue temperature.
These instruments, which are designed to be used either individually or ‘in-tandem’ for simultaneous measurements of tissue oxygenation, blood flow and temperature, are widely used across the globe in areas of biomedical research concerned with hypoxia and ischaemia.
With oxygen sensors based on optical fluorescence technology - pioneered at Oxford Optronix - OxyLite™ Pro is a two- or four-channel oxygen and temperature monitoring instrument that provides continuous, quantitative and high-sensitivity monitoring of oxygen availability to cells and tissue.
This touch-screen based system is remarkably easy to use and is specifically targeted at oxygen measurements in the physiological range, as well as under conditions of hypoxia, offering application in research areas including tumour oxygen monitoring/angiogenesis; cerebral oxygen monitoring in models of stroke and brain injury; vital organ and muscle tissue monitoring; flap monitoring; ophthalmology; wound healing, fMRI-validation techniques; and in-vitro dissolved oxygen monitoring in cell culture and bioreactors.
OxyFlo™ Pro is the company’s third-generation, two- or four-channel laser-Doppler tissue blood flow monitoring instrument.
Oxford Optronix is a pioneer in the development of laser-Doppler based blood flow monitoring (LDF) technology and its latest touch-screen, high-performance system sets a new standard in sensitivity and ease of use.
An ideal system for measuring changing tissue blood flow in acute experimental models, OxyFlo™ Pro offers applications in peripheral vascular disorders; cerebral perfusion monitoring in models of stroke and brain injury; tumour perfusion monitoring/angiogenesis; blood flow in free flaps and pedicle flaps; wound healing; and gastroenterology.
Commenting on the combined system, Dr Hai-Ling Margaret Cheng of University of Toronto, Hospital for Sick Children in Canada said: “In our studies on the response to gas inhalation in abdominal organs, OxyLite and OxyFlo allowed us to monitor tissue pO2 and perfusion response simultaneously in the liver and kidney. No other minimally invasive system could capture dynamic changes with such fine temporal resolution, and no other system could provide concurrent pO2 and perfusion measurement in multiple tissue regions. Oxford Optronix enabled us to understand the physiological phenomena underlying our magnetic resonance imaging measurements. It is truly a powerful, must-have technology.”
Andy Obeid PhD, CEO of Oxford Optronix added: “The release of our new OxyLite™ Pro and OxyFlo™ Pro systems is the culmination of 5 years of continued product development in this area for us.”
He added: “We work closely with our customers to develop targeted solutions that offer unmatched sensitivity, stability and accuracy coupled with total ease-of-use. The introduction of our third-generation platform, enables us to continue providing the ‘gold-standard’ in tissue vitality monitoring that our customers have come to expect.”